Looks like the seller may be done with that spike low. That was a desperation "get out at any cost" sell. Suspect they have been pressuring for a while. Currently in the basing pattern, but has definitely bottomed off, they have cash and their product is starting to get more traction IMO.
Breach of 53 cents brings 70 into play, but LT targets much much higher IMO.
Traction by Company with Phase III approved in Indonesia and progress in Aus trials. Funding from US military also on the radar, and massive R&D refund already locked in for domestic and overseas work means that RCE is only on the hooking for 56.5% of the costs with the 43.5% rebate.
Been a long slow bleed out this one, but think they are turning a corner with a potentially far quicker route to commercial revenues in Indonesia and South East Asia, where diabetic market is huge.
